Antiandrogen apalutamide holds potential for patients with NMIBC.

An interview with Edward M. Messing MD on the apalutamide trial and study on non-muscle invasive bladder cancer in 2024 is presented. When asked on the study's background, he replies that the androgen receptor helps in bladder cancer development, and that the antiandrogen apalutamide has potential to fight the androgen receptor. Messing states that apalutamide will likely reduce the recurrence of this common disease. He notes that the treatment makes castrative therapies more effective.